The role of mitochondrial/metabolic axis in development of tamoxifen resistance in breast cancer

Only a few investigations, to our knowledge, have examined the bioenergetics of Tamoxifen (TMX) resistant individuals and reported altered mitochondrial activity and metabolic profile. The primary cause of TMX resistance is firmly suggested to be metabolic changes. Metabolic variations and hypoxia h...

Full description

Saved in:
Bibliographic Details
Published in:Human cell : official journal of Human Cell Research Society 2023-11, Vol.36 (6), p.1877-1886
Main Authors: Azzam, Hany N., El-Derany, Marwa O., Wahdan, Sara A., Faheim, Reham M., Helal, Gouda K., El-Demerdash, Ebtehal
Format: Article
Language:English
Subjects:
Bioenergetics
Biomedical and Life Sciences
Breast cancer
Carcinogenesis
Cell Biology
Epigenetics
Gynecology
Hypoxia
Hypoxia-inducible factor 1
Life Sciences
Metabolism
Metastases
Oncology
Reproductive Medicine
Review
Review Article
Stem Cells
Surgery
Tamoxifen
Taurine
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Only a few investigations, to our knowledge, have examined the bioenergetics of Tamoxifen (TMX) resistant individuals and reported altered mitochondrial activity and metabolic profile. The primary cause of TMX resistance is firmly suggested to be metabolic changes. Metabolic variations and hypoxia have also been linked in a bidirectional manner. Increased hypoxic levels correlate with early recurrence and proliferation and have a negative therapeutic impact on breast cancer (BC) patients. Hypoxia, carcinogenesis, and patient death are all correlated, resulting in more aggressive traits, a higher chance of metastasis, and TMX resistance. Consequently, we sought to investigate the possible role of the metabolic/hypoxial axis Long non-coding RNA (LncRNA) Taurine up-regulated 1 (TUG-1), Micro-RNA 186-5p (miR-186), Sirtuin-3 (SIRT3), Peroxisome Proliferator Activator Receptor alpha (PPAR-α), and Hypoxia-Inducible Factor-1 (HIF-1) in the development of TMX resistance in BC patients and to correlate this axis with tumor progression. Interestingly, this will be the first time to explore epigenetic regulation of this axis in BC.
ISSN:1749-0774
0914-7470
1749-0774
DOI:10.1007/s13577-023-00977-5